Recent Press Releases

Celsion Announces Positive Interim Data Update from its Phase 2 DIGNITY Study in Breast Cancer

ThermoDox® Continues to Demonstrate Impressive Local Response Rate in Refractory Patients LAWRENCEVILLE, N.J., July 24, 2014 /PRNewswire/ -- Celsion Corporation CLSN +7.43% announced today...

Merck Initiates Phase 3 Study of Letermovir, an Investigational Antiviral for Prevention of Cytomegalovirus (CMV) Infection in High-Risk Bone Marrow Transplant Patients

WHITEHOUSE STATION, N.J., Jul 24, 2014 (BUSINESS WIRE) -- Merck MRK +0.10% , known as MSD outside the United States and Canada, today announced that the first patient has been enrolled in a global...

Pfenex Inc. Announces Pricing Of Initial Public Offering

SAN DIEGO, July 24, 2014 -- Pfenex Inc. (NYSE MKT: PFNX) today announced the pricing of its initial public offering of 8,333,333 shares of its common stock at a price to the public of $6.00 per...

Immune Design Announces Pricing of Initial Public Offering

SEATTLE and SOUTH SAN FRANCISCO, Calif., July 24, 2014 -- Immune Design (IMDZ) announced today the pricing of its initial public offering of 5,000,000 shares of its common stock at a price of $12.00...

Atox Bio Closes $23 Million Investment

NESS ZIONA, Israel--Atox Bio, developer of therapeutics for severe infections, today announced that it has raised up to $23 million in a Series E investment led by SR One with participation by...

Taiho Pharmaceutical Invests US$30 Million in Remiges BioPharma Fund, LP

TOKYO, July 23, 2014 /PRNewswire/ -- - Investment to Foster Early Biotech Start-ups - Taiho Pharmaceutical Co., Ltd. (hereinafter "Taiho"), a fully-fledged oncology pharmaceutical company,...

FDA accepts Sandoz application for biosimilar filgrastim

Sandoz is the first company to announce it has filed for approval of a biologic under the biosimilars pathway created in the Biologics Price Competition and Innovation Act of 2009 (BPCIA). ...

FDA approves Zydelig for three types of blood cancers

The U.S. Food and Drug Administration today approved Zydelig (idelalisib) to treat patients with three types of blood cancers. Zydelig is being granted traditional approval to treat patients whose...

U.S. Food and Drug Administration Approves Gilead's Zydelig® (idelalisib) for Relapsed Chronic Lymphocytic Leukemia, Follicular Lymphoma and Small Lymphocytic Lymphoma

-- 82 Percent Reduction in Risk of Disease Progression or Death When Combined with Rituximab Compared to Rituximab Alone in Patients with Relapsed Chronic Lymphocytic Leukemia -- FOSTER CITY,...

Seven pharma companies offer up compounds to UK researchers

UK researchers will be granted access to a 'virtual library' of deprioritised pharmaceutical compounds through a new partnership between the Medical Research Council (MRC) and seven global...

Halozyme Resumes Patient Enrollment And Dosing In PEGPH20 Clinical Program In Pancreatic Cancer

SAN DIEGO -- Halozyme Therapeutics, Inc. today announced that it has resumed enrollment and dosing of patients in its ongoing Phase 2 trial (Study 202) evaluating PEGPH20 in patients with pancreatic...

Inovio Pharmaceuticals HPV Immunotherapy Achieves Primary Efficacy Endpoint in Randomized Phase II Cervical Dysplasia Trial

Treatment with VGX-3100 induces regression of precancerous cervical disease and clears HPV infection with robust T cell responses PLYMOUTH MEETING, Pa., July 23, 2014 /PRNewswire/ -- Inovio...

Major advance in UCB pipeline: positive topline Phase 3 results for brivaracetam in epilepsy patients with partial-onset seizures

• Brivaracetam is the newest investigational medicine to emerge from UCB's rich late-stage pipeline • Submissions to US and EU regulatory authorities planned for early 2015: subject to...

FDA Approves Eagle Pharmaceuticals' Ryanodex® for the Treatment of Malignant Hyperthermia

FDA Approves Eagle Pharmaceuticals' Ryanodex® for the Treatment of Malignant Hyperthermia -- Novel Antidote Enables Quicker Response to Inherited Life-Threatening Condition ---- Orphan Drug...

Shire Enters Strategic Licensing and Collaboration Agreement With ArmaGen

Strengthens Leadership Position in Treatments for Hunter syndrome and Commitment to MPS II Patient Community LEXINGTON, Massachusetts, July 23, 2014 -- Shire plc (LSE: SHP, NASDAQ: SHPG), the global...

Sofinnova Raises $500 Million Biotech Venture Fund

Sofinnova Raises $500 Million Biotech Venture Fund SVP IX fund to invest primarily in late-stage biopharmaceutical companies MENLO PARK, Calif., July 23, 2014 /PRNewswire/ -- Sofinnova Ventures, a...

Puma Biotechnology Announces Amendment to Neratinib Licensing Agreement with Pfizer

LOS ANGELES--(BUSINESS WIRE)-- Puma Biotechnology, Inc. (PBYI), a development stage biopharmaceutical company, announced an amendment to its licensing agreement with Pfizer for Puma's...

Puma Biotechnology Announces Positive Top Line Results from Phase III PB272 Trial in Adjuvant Breast Cancer (ExteNET Trial)

Neratinib Achieves Statistically Significant Improvement in Disease Free Survival Company Plans to File for Regulatory Approval in First Half of 2015 LOS ANGELES--(BUSINESS WIRE)-- Puma...

Third Product in Vernalis' Cough Cold Pipeline (CCP-08) Achieves Proof-of-Concept

Third Product in Vernalis' Cough Cold Pipeline (CCP-08) Achieves Proof-of-Concept MONMOUTH JUNCTION, N.J., July 22, 2014 /PRNewswire/ -- Vernalis plc UK:VER +1.56% and Tris Pharma, Inc....

Phosphagenics Completes First Tranche of A$19.3 Million Capital Raising

Phosphagenics Completes First Tranche of A$19.3 Million Capital Raising - Sold 153 million shares at A$0.08 per share- A$3 million Share Purchase Plan expected to close July 29 MELBOURNE, Australia,...